Abstract:BACKGROUND:Pancreatic cancer has an enrichment of stem-like cancer cells (CSCs) that contribute to chemoresistant tumors prone to metastasis and recurrence. Drug screening assays based on cytotoxicity cannot identify specific CSC inhibitors, because CSCs comprise only a small portion of cancer cell population, and it is difficult to propagate stable CSC populations in vitro for high-throughput screening (HTS) assays. Based on the important role of cancer cell epithelial-to-mesenchymal transition (EMT) in promoting CSCs, we hypothesized that inhibition of EMT can be a useful strategy for inhibiting CSCs, and therefore a feasible approach for HTS can be built for identification of CSC inhibitors, based on assays detecting EMT inhibition.METHODS:An immunofluorescent assay was established and optimized for HTS to identify compounds that enhance E-cadherin expression, as a hallmark of inhibition of EMT. Four chemical libraries containing 41,472 compounds were screened in PANC-1 pancreatic cancer cell line. Positive hits were validated for EMT and CSC inhibition in vitro using sphere formation assay, western blotting, immune fluorescence, and scratch assay.RESULTS:Initial hits were refined to 73 compounds with a secondary screening, among which 17 exhibited concentration dependent induction of E-cadherin expression. Six compounds were selected for further study which belonged to 2 different chemical structural clusters. A novel compound 1-(benzylsulfonyl) indoline (BSI, Compound #38) significantly inhibited pancreatic cancer cell migration and invasion. BSI inhibited histone deacetylase, increased histone 4 acetylation preferably, resulting in E-cadherin up-regulation. BSI effectively inhibited tumor spheres formation. Six more analogues of BSI were tested for anti-migration and anti-CSC activities.CONCLUSION:This study demonstrated a feasible approach for discovery of agents targeting EMT and CSCs using HTS, and identified a class of novel chemicals that could be developed as anti-EMT and anti-CSC drug leads.

Canadine Platinum(IV) Complexes Targeting Epithelial-Mesenchymal Transition as Antiproliferative and Antimetastatic Agents

Series of Desloratadine Platinum(IV) Hybrids Displaying Potent Antimetastatic Competence by Inhibiting Epithelial-Mesenchymal Transition and Arousing Immune Response

Targeting epithelial-mesenchymal transition: Metal organic network nano-complexes for preventing tumor metastasis

Ursodeoxycholic Acid Platinum(IV) Conjugates as Antiproliferative and Antimetastatic Agents: Remodel the Tumor Microenvironment through Suppressing JAK2/STAT3 Signaling

Platinum(II) N -heterocyclic carbene complexes arrest metastatic tumor growth

Cetirizine Platinum(iv) Complexes with Antihistamine Properties Inhibit Tumor Metastasis by Suppressing Angiogenesis and Boosting Immunity

Transferrin-Modified Carprofen Platinum(IV) Nanoparticles as Antimetastasis Agents with Tumor Targeting, Inflammation Inhibition, Epithelial-Mesenchymal Transition Suppression, and Immune Activation Properties

Anticancer Platinum(IV) Prodrugs Containing Monoaminophosphonate Ester As a Targeting Group Inhibit Matrix Metalloproteinases and Reverse Multidrug Resistance.

Platinum(II) Terpyridine Anticancer Complexes Possessing Multiple Mode of DNA Interaction and EGFR Inhibiting Activity

Overcoming Therapeutic Resistance to Platinum-Based Drugs by Targeting Epithelial–Mesenchymal Transition

Multi-specific Niflumic Acid Platinum(iv) Complexes Displaying Potent Antitumor Activities by Improving Immunity and Suppressing Angiogenesis Besides Causing DNA Damage

Mitochondria-targeting monofunctional platinum(ii)-lonidamine conjugates for cancer cell de-energization

New nano-complexes targeting protein 3S7S in breast cancer and protein 4OO6 in liver cancer investigated in cell line

Mechanism of Anticancer Action of Novel Imidazole Platinum(II) Complex Conjugated with G2 PAMAM-OH Dendrimer in Breast Cancer Cells

Hypotoxic Copper Complexes with Potent Anti-Metastatic and Anti-Angiogenic Activities Against Cancer Cells

Design, Synthesis and Biological Evaluation of Demethylcantharidate-Linked Platinum(ii) Complexes of N-monoalkyl-1R,2R-diaminocyclohexane Derivatives

Targeting Epithelial-Mesenchymal Transition for Identification of Inhibitors for Pancreatic Cancer Cell Invasion and Tumor Spheres Formation.

Towards the Rational Design of Platinum(ii) and Gold(iii) Complexes As Antitumour Agents

Recent Development in Platinum Complexes with Anticancer Activities and the Underlying Mechanisms

Co-targeting CDK 4/6 and C-MYC/STAT3/CCND1 axis and inhibition of tumorigenesis and epithelial-mesenchymal-transition in triple negative breast cancer by Pt(II) complexes bearing NH3 as trans-co-ligand

Platinum(IV) Complexes As Inhibitors of STAT3 and Regulators of the Tumor Microenvironment to Control Breast Cancer.